The industry’s focus on living human beings and the strict regulations that it imposes provide unique considerations for business leaders. These attributes make the industry an ideal platform for innovation. They have resulted in major breakthroughs in biofuels, agricultural yields and life-saving pharmaceuticals.

Biotech startups have a myriad of options when it comes down to revenue generation strategies, with most opting for a technology-based partnership or an asset creation and out-licensing approach. Technology partnering can result in more revenue and reduce risk to the financials, whereas assets creation and outlicensing strategies are able to yield https://genotec-frankfurt.de/top-5-simple-virtual-deal-software-for-beginners/ much more returns. An increasing number of biotechs at the research stage use a hybrid model that combines both strategies.

If you choose to go with a product-oriented strategy are more likely to achieve commercial success as long as they are able to get their pipelines up to the right stage and attract a large pharmaceutical partner or investor with deep pockets. This could be a costly investment. It is essential to balance opportunistic approaches in taking advantage of outside resources and the best scientific decisions for domestic projects.

Alternatively, the “platform” model offers an alternative method of earning revenue. It is less expensive than product-oriented development, but comes with a high risk. In this model, a biotech owns and develops its platform technology before partnering with big pharma companies to develop a portfolio of drug discovery projects that target specific disease areas (i.e. disease the x gene within biology y). Advinus Therapeutics, among others have adopted this strategy.

(1)